The Aducanumab Aftermath: The Payer
from Tradeoffs
A controversial new $56,000 Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers. This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending. Guest: Mark Miller, PhD, Executive Vice President for Health Care, Arnold Ventures Explore the full series and additional resources: https://tradeoffs.org/aducanumab Read a transcript of this episode: https://tradeoffs.org/2021/06/24/the-aducanumab-aftermath-the-payer/ Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletter Support this type of journalism today, with a gift: https://tradeoffs.org/donate Follow us on Twitter: https://twitter.com/tradeoffspod
Embed this episode
No transcript yet.